Výsledky vyhledávání

Biomarker distribution and characteristics for the first 100 patients in MAVERICC, a randomized phase II study of mFOLFOX6-bevacizumab (BV) versus FOLFIRI-BV in previously untreated metastatic colorectal cancer (mCRC)

Autor: Alexander Starodub, Vallathucherry Harish, Romeo Ang Mandanas, Fa-Chyi Lee, Christiane Langer, Tobias Vogt, Suprith Badarinath, Heinz-Josef Lenz, Sang Y. Huh, Han A. Koh, Angelique Mittan, Larry Leon, Edith P. Mitchell, Sachdev P. Thomas

Publikováno v: Journal of Clinical Oncology. 31:483-483

483^ Background: Retrospective analyses have suggested that ERCC1 is a chemo-resistance marker to platinum compounds; a median tumoral ERCC1 level of 1.7 × 10–3ERCC1/β-actin mRNA has been reported in metastatic colon cancer (Grimminger et al, Pha

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2e9a2b4d77ca3985d67a0c3b7d3ddddf
https://doi.org/10.1200/jco.2013.31.4_suppl.483

Zobrazit plný text záznamu

Adjuvant carboplatin, docetaxel, bevacizumab, and erlotinib versus chemotherapy alone in patients with resected non-small cell lung cancer: A randomized phase II study of the Sarah Cannon Research Institute (SCRI)

Autor: John D. Hainsworth, David R. Spigel, James D. Peyton, Mathew John Joseph, Sang Y. Huh, Edward K. Barnes, David Michael Waterhouse, Raven Quinn, Victor G. Gian, Davey B. Daniel, F. A. Greco, Howard A. Burris, Christopher F. Lobo

Publikováno v: Journal of Clinical Oncology. 30:7035-7035

7035 Background: Adjuvant chemotherapy improves overall survival (OS) in patients (pts) with resected non small cell lung cancer (NSCLC). Bevacizumab and erlotinib improve survival in pts with advanced unresectable NSCLC. This randomized phase II mul

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8b5bd6408288e58d2ec8bc4850b3478c
https://doi.org/10.1200/jco.2012.30.15_suppl.7035

Zobrazit plný text záznamu

MAVERICC: A randomized phase II study of mFOLFOX6-bevacizumab (BV) versus FOLFIRI-BV with prospective biomarker stratification in previously untreated metastatic colorectal cancer (mCRC)

Autor: Suprith Badarinath, Kulumani M Sivarajan, Sang Y. Huh, Heinz-Josef Lenz, Christiane Langer, Richard H. Greenberg, Stefan Scherer, Sachdev P. Thomas, Christine Litz Curry, Shibao Feng

Publikováno v: Journal of Clinical Oncology. 30:TPS3635-TPS3635

TPS3635^ Background: The identification of prognostic and predictive biomarkers could significantly improve the risk-benefit ratio and cost-effectiveness of 1st-line mCRC regimens. This is the first prospective study of tumoral ERCC1 (chemo-resistanc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0ff723c126fe7023ba7c6299fb052d55
https://doi.org/10.1200/jco.2012.30.15_suppl.tps3635

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání